通过数据集成,SYNGAP1相关疾病的临床特征
Jillian L McKee1, Jan H Magielski2, Julie Xian2
1Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA; The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA; Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA; Epilepsy and Neurodevelopmental Disorders Center (ENDD), Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
这项研究描述了SYNGAP1疾病症状的纵向进展,揭示了和自闭症的明显的年龄相关模式. 这些发现有助于改善这种遗传神经发育障碍的诊断,预后和临床试验准备.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 发展生物学 发展生物学
背景情况:
- SYNGAP1是一种与,自闭症和智力障碍相关的遗传神经发育障碍.
- 了解SYNGAP1的纵向进展对于临床试验的准备至关重要,因为它的流行率很高.
研究的目的:
- 描述SYNGAP1疾病中的纵向进展,发育轨迹和行为表型.
- 为改善临床护理和试验设计提供对SYNGAP1表型的全面了解.
主要方法:
- 结合电子医疗记录数据 (n=158) 和保险索赔数据 (n=246) 来分析纵向症状进展.
- 在SYNGAP1.1中评估了关键临床特征的与年龄相关的模式和风险因素.
主要成果:
- 确定了SYNGAP1与行为异常 (OR:12.35),一般发作 (OR:1.56) 和自闭症 (OR:12.23) 之间的显著关联.
- 观察到明显的与年龄相关的模式,包括在27-30个月之间增加5倍的自闭症行为风险和3岁后增加发作风险.
- 与其他抗发作药物相比,瓦尔酸和拉莫特里金在管理方面表现出更大的有效性.
结论:
- 在SYNGAP1相关疾病中划分了发作,发育和行为轨迹.
- 这些发现支持改善SYNGAP1.1的诊断,预后和临床管理策略.
- 改进的表征有助于为SYNGAP1干预措施做好临床试验准备.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
相关概念视频
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
